Top Tampa, FL Companies With Best Stability & Growth (1,144)

Innovation-Driven Growth: Recent moves pair a planned constellation expansion that combines higher-resolution imaging with higher revisit rates with an AI-centric platform and new 3D offerings. Together, these signal movement up the value chain toward higher-margin software and systems.

Market Expansion: Statements highlight expanding international activity, including a Bundeswehr-focused joint effort, more than a dozen new European customers in 2025, and 60+ government partners. These point to growing geographic reach and customer adoption.

Strategic Partnerships: Collaborations such as a German JV with Rheinmetall for ISR data integration and a build partnership with BAE Systems on next-generation satellites indicate deepening ecosystem ties. Such alliances can accelerate access to new programs and markets.

Resilient & Sustainable Growth: Revenue increased in FY2024 and again in FY2025 to a record ~US$56.9B, with all three lines of service expanding. Growth in the Americas and EMEA helped offset softness in parts of Asia Pacific, indicating steady, if modest, momentum.

Innovation-Driven Growth: A multi‑year push includes roughly US$1.5B to expand and scale AI capabilities, alongside AI‑enabled platforms and dedicated AI hubs/factories. These investments are positioned to extend growth beyond core assurance and tax and to support new, tech‑enabled offerings.

Strong Market Position & Advantage: As one of the Big Four with record scale and repeated “Leader” placements in independent analyst evaluations, the firm operates from a top‑tier competitive position. Rising brand value and leadership recognition in selected consulting categories reinforce commercial strength.

Profitability: Adjusted EPS advanced at a double‑digit pace in both Q1 and Q2 2026, with adjusted ROE at the high end of the target range, supported by favorable underwriting and stronger net investment income. Capital deployment remained robust alongside these gains.

Future-Ready Strategy: Management’s “New Frontier” plan targets sustained double‑digit adjusted EPS growth and mid‑teens adjusted ROE through 2029. Expansion of fee‑based earnings via MetLife Investment Management—now scaled into the hundreds of billions of AUM with a stated path toward roughly $1T—supports the plan.

Diversified Revenue Streams: Broad‑based momentum across Group Benefits, Retirement & Income Solutions, Asia, Latin America, EMEA, and MIM lifted adjusted earnings and revenue‑related metrics in early 2026. Underlying PFO growth excluding episodic pension risk transfers outpaced headline totals, indicating multiple engines of growth.

Profitability: Operating earnings reached a record $3.6 billion in 2025, up 4% year over year. Consecutive record years through 2024–2025 point to momentum in core earnings performance.

Investor Backing & Capital Strength: Total surplus rose to $34.7 billion in 2025 from $33.3 billion in 2024, and the company reports the highest financial strength ratings across A.M. Best, Fitch, Moody’s, and S&P. A record $2.8 billion dividend declared for 2026 further reflects balance‑sheet depth in a mutual structure.

Product Line Growth: Insurance sales increased 14% and annuity sales rose 40% in 2025, with mutual fund sales up 7%. Individual life insurance in force neared $1.3 trillion and AUM reached about $892 billion at year‑end 2025, indicating broad‑based expansion across offerings.

Strong Revenue Growth: Revenue is described as accelerating sharply, with filings showing substantial year-over-year gains through 2024 and the first nine months of 2025, and independent estimates pointing to a billion‑dollar run rate in 2025. These trends align with rising client activity and balances disclosed alongside product launches.

Investor Backing & Capital Strength: New equity financing in January 2026 co‑led by Baillie Gifford and SBI Holdings, reports of a multibillion‑dollar pre‑IPO valuation, and outstanding senior notes expand financial capacity for scaling. These signals suggest ample capital to support continued build‑out and pre‑IPO positioning.

Market Expansion: Licenses in Europe, an APAC entry via the Boom Securities deal, and a trading app for sophisticated individual investors broaden both geography and customer segments beyond institutional prime brokerage. Cross‑margin and digital‑asset initiatives further indicate expansion into adjacent markets.

Investor Backing & Capital Strength: Advent International agreed on August 25, 2025 to acquire PatientPoint, with reporting at more than $1.4B, providing external validation and resources to accelerate expansion. This backing is positioned to support network growth and product innovation.

Product Line Growth: In March 2026 PatientPoint launched programmatic buying (Health Audiences) and a Consumer Health Network aimed at CPG/OTC brands, expanding how advertisers can buy and who the company serves. These additions broaden monetization beyond traditional life‑sciences sponsors.

Strong Market Position & Advantage: PatientPoint reports a nationwide footprint in 30,000+ physician offices and 125,000 providers, and in April 2026 received expanded Media Rating Council accreditation across its full digital screen network. This scale and third‑party validation bolster credibility for national buys.

Strong Revenue Growth: Recent disclosures cite being on track to do more than $500M in net revenue for the fiscal year ending May 31 and a rise in a contribution metric from roughly $140M (2022) to about $350M (2024). Earlier filings also reported 32% year-over-year revenue growth in FY2021, indicating multi-year top-line expansion.

Product Line Growth: The company expanded beyond its core PEO with a standalone Payroll product, Employer of Record capabilities in Canada, and a 2026 ICHRA partnership with Thatch. These additions signal investment in adjacent offerings that can drive incremental growth.

Market Expansion: Customer counts progressed from nearly 9,000 (2022) to 12,000+ (2024/2025) and to about 15,000 in a 2026 CEO note, alongside 30% more new customers year over year. Operating throughput reached $31B+ in payroll processed and 268K+ W‑2s in 2025, consistent with a broader footprint.

Strong Revenue Growth: Net sales rose 6.8% in 2025 to $22.4B and accelerated to 9.2% in Q1 2026 and 10.0% in Q2 2026, with non‑GAAP EPS also increasing. Management continues to target outgrowing the U.S. IT addressable market by 200–300 bps.

Diversified Customer Base: Growth was broad across Commercial (+9.2%), Government (+13.6%), Education (+0.7%), and international “Other” (+22.9%) in Q2 2026, with 2025 gains led by Small Business, Corporate, and UK/Canada. This breadth helps smooth spending cycles and supports share gains.

Healthy Cash Flow: Regular capital returns continued, highlighted by a $0.63 quarterly dividend declared for September 10, 2026. Operating income and non‑GAAP earnings increased, indicating ongoing cash generation to fund dividends.

Market Expansion: After the March 2024 acquisition, Ashley broadened Resident’s in‑store and online presence, rolling out a new Nectar lineup across its network by late September 2024 and extending international reach. This materially increases brick‑and‑mortar exposure and channel access for the portfolio.

Strong Market Position & Advantage: Resident entered the deal as a hyper‑growth DTC house of brands at significant scale and is now amplified by Ashley’s retail and manufacturing footprint. This combination strengthens distribution leverage across DTC, wholesale, and stores.

Innovation-Driven Growth: New digital initiatives, including an AI‑enabled shopping experience in partnership with PayPal/Perplexity, signal ongoing investment in technology and experimentation. Directional ecommerce trackers also indicate online traction has not stalled.

Strong Revenue Growth: Company posts indicate it finished 2025 at about $2.7B in revenue with a Q4 run-rate near $3B, alongside >25% truckload volume growth. Earlier disclosures show a climb from ~$0.8B in 2020 to the billions by 2025, reflecting a sustained top-line expansion.

Profitability: Leadership highlights positive net income in 2025 and notes the business ended 2024 profitably. Growth investments in technology and expansion are being pursued alongside earnings, underscoring disciplined scaling.

Cost & Operational Efficiency: Internal cost per load fell and management reports productivity gains tied to its technology platform, with further improvements targeted in 2025. These efficiency trends are presented as levers to manage volatility while scaling.

Market Expansion: Facility additions and enlargements—including Fort Worth and Reno supercenters, a new Mississauga branch, and a larger Atlanta-area distribution center in Buford—are cited alongside a network of 18 North American locations, signaling a broader footprint. Recent sales-agent appointments across the U.S. and Canada (e.g., Blue Sky Reps, Rowe Sales, Electrical Lines, expanded DSI Southwest) further extend regional coverage.

Product Line Growth: A dedicated Communications Business Unit (March 2024) and an expanded industrial automation portfolio (May 2024) move the company into faster-growing segments like fiber/broadband and factory automation. Added authorizations and offerings such as major circuit breakers, nVent CADDY, Dura-Line, Lynn Networks, and TiniFiber expand category breadth.

Strategic Partnerships: Exclusive redistribution for TiniFiber’s Micro Armor fiber and new or expanded alliances with brands like Dura-Line and Lynn Networks strengthen supplier access and inventory relevance across 18 locations. Additional manufacturer-rep coverage (e.g., Blue Sky Reps and TMC Sales in Canada) improves channel reach and customer access.

Product Line Growth: Launched and acquired products are expanding at a double‑digit pace (e.g., +18% operational in Q2 2026), led by assets such as Eliquis, Padcev, the Vyndaqel family, and Lorbrena. Excluding Comirnaty and Paxlovid, revenue grew mid‑single digits, signaling healthy momentum in the core portfolio.

Cost & Operational Efficiency: A multi‑year cost realignment targets about $5.7B in net savings by end‑2026, with a further $2.5B in productivity gains planned for 2027–2029. These actions have supported improved adjusted earnings even as headline revenue normalizes post‑COVID.

Innovation-Driven Growth: A robust late‑stage pipeline and oncology expansion following the Seagen acquisition underpin future growth, with numerous pivotal study starts in 2025–2026. Company commentary highlights oncology and obesity programs as key catalysts into the back half of the decade.

Profitability: Q2 2026 delivered positive GAAP operating income of $3.0M and non‑GAAP operating income of $28.9M, with management raising the 2026 non‑GAAP operating income outlook. This indicates margin improvement even as the top line softens.

Healthy Cash Flow: Free cash flow was $31.9M in Q2 2026 and management is targeting around $125–$135M for full‑year 2026. This ongoing cash generation underscores improved efficiency during a reset year.

Investor Backing & Capital Strength: Cash and short‑term investments increased to about $703M as of June 30, 2026, up from roughly $657M at year‑end 2025. This liquidity provides flexibility amid slower ARR and revenue trends.

Strong Market Position & Advantage: The company operates at top‑tier national scale among U.S. PEOs and is identified head‑to‑head with ADP TotalSource, Paychex PEO, and Insperity. A large base of worksite employees and expanded HRIS capabilities via Zenefits support national competitiveness.

Healthy Cash Flow: Free cash flow increased year over year in 2025 and the company returned over $200 million via repurchases and dividends. Authorization for share repurchases was expanded in early 2026, signaling capacity to fund capital returns.

Cost & Operational Efficiency: Management tightened the insurance cost ratio in 2025 with a narrower target range for 2026 and reduced operating expenses. Margin discipline is reinforced by efforts to control insurance costs and streamline operating spend.

Strong Revenue Growth: Record 2025 gross revenue and an improved Am Law 100 ranking indicate sustained top-line momentum. Revenue per lawyer also rose, signaling growth not solely driven by headcount.

Profitability: Profits per equity partner and net income increased materially alongside revenue. These gains were attributed to heightened demand across departments.

Market Expansion: New offices in Raleigh and Nashville, plus sustained lateral partner additions (notably in California), expanded the firm’s footprint. The platform now spans roughly 1,100 lawyers across 27 offices supporting national coverage.

Strong Market Position & Advantage: Market leadership is evident in the company’s repeated top rankings in agency multifamily lending, including being the largest Fannie Mae lender for multiple consecutive years and a top combined GSE originator. Strong standing is also reflected in multifamily investment sales league-table positions and a large servicing portfolio that supports recurring platform relevance.

Strong Revenue Growth: Business activity expanded materially in 2025, with total transaction volume rising sharply year over year and revenue increasing versus 2024. Capital markets and multifamily property sales volumes also accelerated through 2025, indicating a broad rebound in core operating throughput.

Future-Ready Strategy: Forward guidance and stated long-term targets point to a plan for improving earnings power as transaction activity normalizes and extraordinary charges moderate. A significantly stronger near-term pipeline entering 2026 reinforces the expectation of continued momentum.

Strong Market Position & Advantage: Following the June 2025 combination with Moss Adams, the firm is described as moving into a top-six U.S. position by net revenue, placing it in the national top tier below the Big Four. The expanded national coverage and sector depth are positioned as improving competitiveness for middle-market and upper-middle-market clients.

Strong Revenue Growth: Record results are cited for the wider network, including a year marked by large year-over-year revenue expansion, with North America highlighted as the fastest-growing region and the U.S. merger noted as a key driver. The company is repeatedly characterized as being in an accelerated growth phase since 2024–2025, supported by increased scale and continued add-on deals.

Investor Backing & Capital Strength: A strategic private-equity investment is cited as providing capital to fund a more aggressive expansion strategy and buy-and-build approach. The shift to an alternative practice structure is framed as enabling growth investment across advisory capabilities and acquisitions.

Strong Market Position & Advantage: Feedback suggests AdventHealth is a top‑tier U.S. health system with clear regional leadership and a flagship recognized on national honor rolls, supporting a durable competitive position.

Strong Revenue Growth: Evidence points to rising system revenues and improved operating performance, enabling continued capital investment and expansion.

Market Expansion: Multiple acquisitions, new hospitals, and major campus projects across growth markets indicate ongoing geographic and capacity expansion.